RxDoctor Payments Data

Louis D'avignon, MD

Pulmonary Disease · Bend, ORNPI 1760583389

Payments from drug & device makers

What this record shows

This record is dominated by education: $2,534 of the $3,994 with a category attached, or 63.4%. Intuitive Surgical accounts for 97.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $3,878 and has fallen 98.6% since, to $54 in 2025.

$3,994in general payments, 2019–2025

Across 17 payments — averaging $234.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Actelion Pharmaceuticals US, Inc.$37
  • Insmed, Inc.$34
  • Amarin Pharma, Inc.$22
  • Circassia Inc.$12
  • GSK$11

What the payments were for

  • Travel & lodging$1,22831%
  • Food & beverage$2326%
  • Education$2,53463%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical11$3,878
Actelion Pharmaceuticals US, Inc.1$37
Insmed, Inc.2$34
Amarin Pharma, Inc.1$22
Circassia Inc.1$12
GSK1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,994 in reported general payments places this provider in the 80th percentile of 154 pulmonary disease providers in Oregon.

See all pulmonary disease providers in Oregon

Medicare billing

Part B allowed, 2024
$675,533
Medicare patients
477
Services billed
7,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate19$265,128
Trelegy ElliptaFluticasone/Umeclidin/Vilanter296$248,502
Pirfenidone30$73,463
Breo ElliptaFluticasone/Vilanterol81$48,498
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr65$39,073
EliquisApixaban30$36,280
Spiriva RespimatTiotropium Bromide42$25,637
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate117$21,764
Qvar RedihalerBeclomethasone Dipropionate45$15,660
DuleraMometasone/Formoterol29$14,673
Stiolto RespimatTiotropium Br/Olodaterol Hcl21$13,581
Fluticasone-SalmeterolFluticasone Propion/Salmeterol114$13,541
JardianceEmpagliflozin13$9,992
Fluticasone-VilanterolFluticasone/Vilanterol35$8,297
SymbicortBudesonide/Formoterol Fumarate23$7,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$11$343,399455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 154 pulmonary disease providers in Oregon.

Other pulmonary disease in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →